Ernest Agatstein, MD
Urology · Downey, CANPI 1952386583
Payments from drug & device makers
Across 269 payments — averaging $44.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$6K
- Astellas Pharma US Inc$966
- Pfizer$633
- Bayer$551
- Teleflex LLC$493
- Axonics, Inc.$457
- plus $3K from 33 others
What the payments were for
- Consulting fees$5,56547%
- Travel & lodging$2242%
- Food & beverage$5,42946%
- Education$6676%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 17 | $6,012 |
| Astellas Pharma US Inc | 38 | $966 |
| Pfizer | 39 | $633 |
| Bayer | 43 | $551 |
| Teleflex LLC | 12 | $493 |
| Axonics, Inc. | 15 | $457 |
| Sumitomo Pharma America, Inc. | 17 | $325 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $274 |
| AbbVie | 12 | $254 |
| Coloplast | 9 | $239 |
| Procept Biorobotics Corporation | 2 | $170 |
| Myriad Genetic Laboratories, Inc. | 7 | $161 |
| Johnson & Johnson(2 entities) | 7 | $150 |
| Sun Pharmaceutical Industries Inc. | 3 | $104 |
| Merck | 5 | $100 |
| Bard Access Systems, Inc. | 1 | $98 |
| Blue Earth Diagnostics | 3 | $78 |
| Urogen Pharma, Inc. | 2 | $68 |
| Foundation Medicine, Inc. | 2 | $66 |
| Progenics Pharmaceuticals, Inc. | 3 | $64 |
| Urovant Sciences Inc | 3 | $62 |
| Novartis | 2 | $50 |
| Myovant Sciences Inc. | 2 | $49 |
| Photocure Inc | 2 | $48 |
| Immunitybio, Inc. | 2 | $47 |
| Hollister Incorporated | 3 | $42 |
| Neotract Inc. | 2 | $36 |
| Valencia Technologies Corporation | 2 | $35 |
| Endo Pharmaceuticals Inc. | 2 | $34 |
| Gilead | 1 | $30 |
| Profound Medical Corp. | 1 | $26 |
| Boston Scientific | 1 | $25 |
| 180 Medical, Inc. | 1 | $25 |
| Medtronic | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $20 |
| Metuchen Pharmaceuticals | 1 | $17 |
| Antares Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$5,539
- AquaBeam Robotic System$142
- UroLift System$138
- Axonics$138
How this compares
$11,885 in reported general payments places this provider in the 75th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 193 | $495,433 |
| XtandiEnzalutamide | 23 | $315,592 |
| NubeqaDarolutamide | 12 | $152,847 |
| GemtesaVibegron | 123 | $99,723 |
| MyrbetriqMirabegron | 64 | $59,176 |
| Tamsulosin Hcl | 768 | $11,009 |
| Oxybutynin Chloride ErOxybutynin Chloride | 185 | $5,192 |
| Finasteride | 390 | $4,640 |
| Solifenacin Succinate | 90 | $4,564 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $4,224 |
| Silodosin | 22 | $4,097 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 180 | $3,800 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $2,295 |
| Dutasteride | 31 | $1,207 |
| Testosterone | 15 | $950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $325 | $595,155316 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $966 | $374,76887 claims |
| BayerNubeqa | $551 | $152,84712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,324 urology providers in California.
Other urology in Downey
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.